Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 2Leukemia, Myeloid, Acute 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Colorectal Neoplasms 2Adenoviridae Infections 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1

Interventions

Carboplatin 5Paclitaxel 4pembrolizumab 3Educational Status 3niraparib 2anlotinib 2Therapeutic Touch 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy 2Pemetrexed 2Palliative Care 2Nivolumab 2Methods 2Interviews as Topic 2Gemcitabine 2Early Intervention, Educational 2Bevacizumab 2temsirolimus 1rucaparib 1relacorilant 1olaparib 1nintedanib 1nilotinib 1liposomal doxorubicin 1lenvatinib 1fosaprepitant 1atezolizumab 1argatroban 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × Cell Count × Clear all
NCT05617755 2025-07-30

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

Arsenal Biosciences, Inc.

Phase 1 Active not recruiting
19 enrolled
Gynecologic

Abdominal Neoplasms, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡